NewLink Genetics Corp (NASDAQ:NLNK) – Equities research analysts at Jefferies Group issued their Q1 2018 earnings per share estimates for NewLink Genetics in a report issued on Friday, Zacks Investment Research reports. Jefferies Group analyst B. Amin expects that the biotechnology company will post earnings per share of ($0.51) for the quarter. Jefferies Group also issued estimates for NewLink Genetics’ Q3 2018 earnings at ($0.62) EPS.
NLNK has been the subject of several other reports. Cantor Fitzgerald set a $26.00 price target on shares of NewLink Genetics and gave the company a “buy” rating in a report on Friday, March 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $21.00 price target (down from $25.00) on shares of NewLink Genetics in a report on Friday, March 2nd. Bank of America cut their price target on shares of NewLink Genetics from $22.00 to $18.00 and set a “buy” rating for the company in a report on Friday, March 2nd. Zacks Investment Research raised shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $9.00 price target for the company in a report on Wednesday, January 3rd. Finally, BidaskClub raised shares of NewLink Genetics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. NewLink Genetics presently has a consensus rating of “Buy” and an average price target of $21.57.
Shares of NewLink Genetics (NLNK) traded up $0.01 during trading hours on Monday, reaching $8.13. 87,394 shares of the company’s stock traded hands, compared to its average volume of 824,198. NewLink Genetics has a 1 year low of $5.90 and a 1 year high of $25.17. The company has a market cap of $305.05, a P/E ratio of -3.46 and a beta of 1.25.
Several hedge funds and other institutional investors have recently bought and sold shares of NLNK. Millennium Management LLC lifted its holdings in shares of NewLink Genetics by 56.6% during the 4th quarter. Millennium Management LLC now owns 2,347,359 shares of the biotechnology company’s stock worth $19,037,000 after acquiring an additional 848,752 shares during the last quarter. Redmile Group LLC lifted its holdings in shares of NewLink Genetics by 67.9% during the 4th quarter. Redmile Group LLC now owns 2,096,490 shares of the biotechnology company’s stock worth $17,003,000 after acquiring an additional 847,790 shares during the last quarter. Perceptive Advisors LLC bought a new stake in shares of NewLink Genetics during the 3rd quarter worth $4,581,000. BlackRock Inc. lifted its holdings in shares of NewLink Genetics by 21.3% during the 4th quarter. BlackRock Inc. now owns 2,311,834 shares of the biotechnology company’s stock worth $18,750,000 after acquiring an additional 405,820 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its holdings in shares of NewLink Genetics by 337.3% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 328,000 shares of the biotechnology company’s stock worth $3,339,000 after acquiring an additional 253,000 shares during the last quarter. 65.14% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Brokers Offer Predictions for NewLink Genetics Corp’s Q1 2018 Earnings (NASDAQ:NLNK)” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://ledgergazette.com/2018/03/14/equities-analysts-issue-forecasts-for-newlink-genetics-corps-q1-2018-earnings-nlnk.html.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.